• Product name
    Anti-Eph receptor B2 antibody
    See all Eph receptor B2 primary antibodies
  • Description
    Rabbit polyclonal to Eph receptor B2
  • Host species
  • Tested applications
    Suitable for: ICC/IF, IHC-P, ELISA, WBmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    Synthetic peptide conjugated to KLH, corresponding to amino acids 118-133 of Human Eph B2.

  • Positive control
    • Mouse heart tissue lysate.



Our Abpromise guarantee covers the use of ab5418 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notes
    ELISA: 1/1000.
    WB: 1/100 - 1/500. Detects a band of approximately 116 kDa (predicted molecular weight: 118 kDa).

    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • Function
      Receptor for members of the ephrin-B family. Phosphorylates ARHGEF15, leading to its ubiquitination and degradation by the proteasome which promotes EFNB1-dependent synapse formation. Can function in aspects of retinal ganglion cell axon guidance to the optic disk even when lacking its tyrosine kinase domain. Acts as a tumor suppressor.
    • Tissue specificity
      Brain, heart, lung, kidney, placenta, pancreas, liver and skeletal muscle. Preferentially expressed in fetal brain.
    • Involvement in disease
      Defects in EPHB2 may be a cause of susceptibility to prostate cancer (PC) [MIM:176807]. It is a malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. Note=EPHB2 mutations have been found in a prostate cancer cell line derived from a brain metastasis.
    • Sequence similarities
      Belongs to the protein kinase superfamily. Tyr protein kinase family. Ephrin receptor subfamily.
      Contains 2 fibronectin type-III domains.
      Contains 1 protein kinase domain.
      Contains 1 SAM (sterile alpha motif) domain.
    • Cellular localization
    • Information by UniProt
    • Database links
    • Alternative names
      • cek5 antibody
      • Developmentally regulated EPH related tyrosine kinase antibody
      • DRT antibody
      • EK5 antibody
      • ELK related protein tyrosine kinase antibody
      • Eph receptor B2 antibody
      • EPH tyrosine kinase 3 antibody
      • EPH-like kinase 5 antibody
      • EPHB2 antibody
      • EPHB2_HUMAN antibody
      • Ephrin type B receptor 2 antibody
      • Ephrin type-B receptor 2 antibody
      • EPHT 3 antibody
      • ERK antibody
      • ETECK antibody
      • hEK5 antibody
      • Nuk antibody
      • Prkm 5 antibody
      • Receptor protein tyrosine kinase HEK 5 antibody
      • Renal carcinoma antigen NY-REN-47 antibody
      • Sek 3 antibody
      • Tyro 5 antibody
      • Tyrosine protein kinase receptor CEK 5 antibody
      • Tyrosine protein kinase receptor EPH 3 antibody
      • Tyrosine protein kinase receptor QEK 5 antibody
      • Tyrosine-protein kinase receptor EPH-3 antibody
      • Tyrosine-protein kinase TYRO5 antibody
      see all


    • Anti-Eph receptor B2 antibody (ab5418) at 1/100 dilution + mouse heart tissue lysate at 0.01 µg

      Developed using the ECL technique.

      Predicted band size: 118 kDa
      Observed band size: 118 kDa
      Additional bands at: 48 kDa (possible isoform)

      ab5418 at a 1/100 dilution staining approximately 116kDa band of Eph B2 in mouse heart tissue lysate by Western blot (ECL).
    • Human cancer tissue stained with ab5418 followed by peroxidase-conjugated secondary antibody and AEC.
    • ICC/IF image of ab5418 stained SKNSH cells. The cells were 4% PFA fixed (10mins) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab5418, 5µg/ml) overnight at +4°C. The secondary antibody (green) was ab96899 Dylight 488 goat anti-rabbit IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.


    This product has been referenced in:
    • Song Y  et al. A novel mechanism of synaptic and cognitive impairments mediated via microRNA-30b in Alzheimer's disease. EBioMedicine N/A:N/A (2018). Read more (PubMed: 30522932) »
    • Zhang C  et al. Growth of tyrosine kinase inhibitor-resistant Philadelphia-positive acute lymphoblastic leukemia: Role of bone marrow stromal cells. Oncol Lett 13:2059-2070 (2017). WB . Read more (PubMed: 28454362) »
    See all 5 Publications for this product

    Customer reviews and Q&As

    Filter by Application

    Filter by Species

    Filter by Ratings

    Western blot
    Human Cell lysate - whole cell (SW480/SW620/LoVo/K9/Jurkate)
    Loading amount
    8 µg
    Gel Running Conditions
    Non-reduced Denaturing
    Blocking step
    Milk as blocking agent for 24 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 4°C

    Dr. Tao Fu

    Verified customer

    Submitted Dec 17 2007

    For licensing inquiries, please contact partnerships@abcam.com

    Sign up